These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1021 related articles for article (PubMed ID: 17846259)

  • 1. Exercise and pharmacotherapy in the treatment of major depressive disorder.
    Blumenthal JA; Babyak MA; Doraiswamy PM; Watkins L; Hoffman BM; Barbour KA; Herman S; Craighead WE; Brosse AL; Waugh R; Hinderliter A; Sherwood A
    Psychosom Med; 2007; 69(7):587-96. PubMed ID: 17846259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel Augmentation Strategies in Major Depression.
    Martiny K
    Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exercise and pharmacotherapy in patients with major depression: one-year follow-up of the SMILE study.
    Hoffman BM; Babyak MA; Craighead WE; Sherwood A; Doraiswamy PM; Coons MJ; Blumenthal JA
    Psychosom Med; 2011; 73(2):127-33. PubMed ID: 21148807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjunctive low-dose aripiprazole with standard-dose sertraline in treating fresh major depressive disorder: a randomized, double-blind, controlled study.
    Lin CH; Lin SH; Jang FL
    J Clin Psychopharmacol; 2011 Oct; 31(5):563-8. PubMed ID: 21869699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short-term dynamic psychotherapy versus pharmacotherapy for major depressive disorder: a randomized, placebo-controlled trial.
    Barber JP; Barrett MS; Gallop R; Rynn MA; Rickels K
    J Clin Psychiatry; 2012 Jan; 73(1):66-73. PubMed ID: 22152401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Exercise and Sertraline on Measures of Coronary Heart Disease Risk in Patients With Major Depression: Results From the SMILE-II Randomized Clinical Trial.
    Sherwood A; Blumenthal JA; Smith PJ; Watkins LL; Hoffman BM; Hinderliter AL
    Psychosom Med; 2016 Jun; 78(5):602-9. PubMed ID: 26867076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sertraline Versus Placebo in Patients with Major Depressive Disorder Undergoing Hemodialysis: A Randomized, Controlled Feasibility Trial.
    Friedli K; Guirguis A; Almond M; Day C; Chilcot J; Da Silva-Gane M; Davenport A; Fineberg NA; Spencer B; Wellsted D; Farrington K
    Clin J Am Soc Nephrol; 2017 Feb; 12(2):280-286. PubMed ID: 28126706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
    Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
    Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: randomized double-blind placebo-controlled study.
    Abbasi SH; Hosseini F; Modabbernia A; Ashrafi M; Akhondzadeh S
    J Affect Disord; 2012 Dec; 141(2-3):308-14. PubMed ID: 22516310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Hypericum perforatum (St John's wort) in major depressive disorder: a randomized controlled trial.
    ; Davidson JR; Gadde KM; Fairbank JA; Krishnan KRR; Califf RM; Binanay C; Parker CB; Pugh N; Hartwell TD; Vitiello B; Ritz L; Severe J; Cole JO; de Battista C; Doraiswamy PM; Feighner JP; Keck P; Kelsey J; Lin KM; Londborg PD; Nemeroff CB; Schatzberg AF; Sheehan DV; Srivastava RK; Taylor L; Trivedi MH; Weisler RH
    JAMA; 2002 Apr; 287(14):1807-14. PubMed ID: 11939866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rhodiola rosea versus sertraline for major depressive disorder: A randomized placebo-controlled trial.
    Mao JJ; Xie SX; Zee J; Soeller I; Li QS; Rockwell K; Amsterdam JD
    Phytomedicine; 2015 Mar; 22(3):394-9. PubMed ID: 25837277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study.
    Marcus RN; McQuade RD; Carson WH; Hennicken D; Fava M; Simon JS; Trivedi MH; Thase ME; Berman RM
    J Clin Psychopharmacol; 2008 Apr; 28(2):156-65. PubMed ID: 18344725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A 6-week randomized, placebo-controlled trial of CP-316,311 (a selective CRH1 antagonist) in the treatment of major depression.
    Binneman B; Feltner D; Kolluri S; Shi Y; Qiu R; Stiger T
    Am J Psychiatry; 2008 May; 165(5):617-20. PubMed ID: 18413705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Omega-3 augmentation of sertraline in treatment of depression in patients with coronary heart disease: a randomized controlled trial.
    Carney RM; Freedland KE; Rubin EH; Rich MW; Steinmeyer BC; Harris WS
    JAMA; 2009 Oct; 302(15):1651-7. PubMed ID: 19843899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exercise and pharmacological treatment of depressive symptoms in patients with coronary heart disease: results from the UPBEAT (Understanding the Prognostic Benefits of Exercise and Antidepressant Therapy) study.
    Blumenthal JA; Sherwood A; Babyak MA; Watkins LL; Smith PJ; Hoffman BM; O'Hayer CV; Mabe S; Johnson J; Doraiswamy PM; Jiang W; Schocken DD; Hinderliter AL
    J Am Coll Cardiol; 2012 Sep; 60(12):1053-63. PubMed ID: 22858387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study.
    El-Khalili N; Joyce M; Atkinson S; Buynak RJ; Datto C; Lindgren P; Eriksson H
    Int J Neuropsychopharmacol; 2010 Aug; 13(7):917-32. PubMed ID: 20175941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antidepressants effects of Rhodiola capsule combined with sertraline for major depressive disorder: A randomized double-blind placebo-controlled clinical trial.
    Gao L; Wu C; Liao Y; Wang J
    J Affect Disord; 2020 Mar; 265():99-103. PubMed ID: 32090788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antidepressant monotherapy vs sequential pharmacotherapy and mindfulness-based cognitive therapy, or placebo, for relapse prophylaxis in recurrent depression.
    Segal ZV; Bieling P; Young T; MacQueen G; Cooke R; Martin L; Bloch R; Levitan RD
    Arch Gen Psychiatry; 2010 Dec; 67(12):1256-64. PubMed ID: 21135325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sertraline for Major Depression During the Year Following Traumatic Brain Injury: A Randomized Controlled Trial.
    Fann JR; Bombardier CH; Temkin N; Esselman P; Warms C; Barber J; Dikmen S
    J Head Trauma Rehabil; 2017; 32(5):332-342. PubMed ID: 28520672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized, proof-of-concept trial of low dose naltrexone for patients with breakthrough symptoms of major depressive disorder on antidepressants.
    Mischoulon D; Hylek L; Yeung AS; Clain AJ; Baer L; Cusin C; Ionescu DF; Alpert JE; Soskin DP; Fava M
    J Affect Disord; 2017 Jan; 208():6-14. PubMed ID: 27736689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 52.